IL‐6 in diabetes and cardiovascular complications
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
IL‐6 is a pleiotropic cytokine that participates in normal functions of the immune system, haematopoiesis, metabolism, as well as in the pathogenesis of metabolic and cardiovascular diseases. Both pro‐ and anti‐inflammatory roles of IL‐6 have been described, which are distinguished by different cascades of signalling transduction, namely classic and trans‐signalling. The present review summarizes the basic principles of IL‐6 signalling and discusses its roles in diabetes and associated cardiovascular complications, with emphasis on the different outcomes mediated by the two modes of IL‐6 signalling and the value of developing therapeutic strategies to specifically target the deleterious trans‐signalling of IL‐6.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Pradhan, A. D. (2001) · JAMA · doi:10.1001/jama.286.3.327 · Cited by 4,433
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272 · cited 1×
“In addition to JAK/ STAT activation, the SRC homology domain 2-containing tyrosine phosphatase 2 (SHP-2) is recruited to its binding site on gp130 and phosphorylated to initiate the MAPK cascade (Heinrich et al., 2003; McFarland-Mancini et al., 2010).”
BackgroundThe pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212 · cited 1×
“Although IL-6 is mostly regarded as a pro-inflammatory cytokine that promotes inflammation under various pathological conditions, its anti-inflammatory and regenerative properties have been increasingly recognized (Scheller et al., 2011).”
BackgroundChiu, J.-J., & Chien, S. (2011) · Physiological Reviews · doi:10.1152/physrev.00047.2009 · Cited by 2,280 · cited 1×
“The atherogenesis is initiated by endothelial dysfunction and structural alterations at those sites in the vasculature susceptible to disturbed laminar flow (Chiu and Chien, 2011), and subsequent infiltration of intimal immune cells (Weber and Noels, 2011).”
BackgroundInterleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130 · cited 1×
“…and, in turn, translocated to the nucleus and then bind to DNA of target genes including acute phase proteins in liver, ‘suppressor of cytokine signalling’ proteins that negatively regulate JAK/ STAT signalling, and a variety of other genes (illustrated in Figure 1, middle) (Heinrich et al., 1998).”
BackgroundVan Snick, J. (1990) · Annual Review of Immunology · doi:10.1146/annurev.iy.08.040190.001345 · Cited by 1,890
Inflammatory Cytokines and the Risk to Develop Type 2 Diabetes
Spranger, J., Kroke, A., Möhlig, M., Hoffmann, K., Bergmann, M. M., Ristow, M., Boeing, H., & Pfeiffer, A. F. H. (2003) · Diabetes · doi:10.2337/diabetes.52.3.812 · Cited by 1,493
Interleukin-6-deficient mice develop mature-onset obesity
Wallenius, V., Wallenius, K., Ahrén, B., Rudling, M., Carlsten, H., Dickson, S. L., Ohlsson, C., & Jansson, J.-O. (2002) · Nature Medicine · doi:10.1038/nm0102-75 · Cited by 1,213 · cited 1×
“In the present context, it is important to note that IL-6deficient mice develop mature-onset obesity, hepatic inflammation and systemic insulin resistance (Wallenius et al., 2002; Matthews et al., 2010).”
Background(2012) · The Lancet · doi:10.1016/s0140-6736(12)60110-x · Cited by 1,146
Steensberg, A., van Hall, G., Osada, T., Sacchetti, M., Saltin, B., & Pedersen, B. K. (2000) · The Journal of Physiology · doi:10.1111/j.1469-7793.2000.00237.x · Cited by 1,095 · cited 1×
“Moreover, IL-6 released from contracting skeletal muscle during exercise can increase circulating levels to 100 pg·mL and this response is much greater than those of other cytokines involved (Pedersen, 2000; Steensberg et al., 2000).”
BackgroundRose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040 · cited 2×
“The anti-inflammatory and regenerative activities of IL-6 are generally mediated by the classic signalling mode, whereas pro-inflammatory responses in many pathological conditions involve trans-signalling (Rabe et al., 2008; Rose-John, 2012).”
BackgroundCarey, A. L., Steinberg, G. R., Macaulay, S. L., Thomas, W. G., Holmes, A. G., Ramm, G., Prelovsek, O., Hohnen-Behrens, C., Watt, M. J., James, D. E., et al. (2006) · Diabetes · doi:10.2337/db05-1404 · Cited by 898
(2012) · The Lancet · doi:10.1016/s0140-6736(11)61931-4 · Cited by 823
Inflammatory Markers and Risk of Type 2 Diabetes
Wang, X., Bao, W., Liu, J., OuYang, Y.-Y., Wang, D., Rong, S., Xiao, X., Shan, Z.-L., Zhang, Y., Yao, P., et al. (2013) · Diabetes Care · doi:10.2337/dc12-0702 · Cited by 820
Self-citationEvidence that interleukin-6 is produced in human skeletal muscle during prolonged running
Ostrowski, K., Rohde, T., Zacho, M., Asp, S., & Pedersen, B. K. (1998) · The Journal of Physiology · doi:10.1111/j.1469-7793.1998.949bp.x · Cited by 673 · cited 1×
“The circulating concentration of IL-6 in humans ranges from approximately 1 pg·mL in healthy individuals, with a several-fold surge in chronic inflammation, a hundredfold after physical exercise, to fatal levels of greater than 1 μg·mL in sepsis (Hack et al., 1989; Waage et al., 1989; Ostrowski et al., 1998; Ruotsalai…”
BackgroundBiologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma
Hideshima, T., Nakamura, N., Chauhan, D., & Anderson, K. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204833 · Cited by 478 · cited 1×
“Moreover, IL-6 can activate the PI3K/Akt pathway in hepatocytes, cardiomyocyte and certain cancer cell lines, where it confers protective effects against cell apoptosis (Hideshima et al., 2001; Zhang et al., 2003; Smart et al., 2006; Chou et al., 2013).”
BackgroundInterleukin-6 Is a Novel Factor Mediating Glucose Homeostasis During Skeletal Muscle Contraction
Febbraio, M. A., Hiscock, N., Sacchetti, M., Fischer, C. P., & Pedersen, B. K. (2004) · Diabetes · doi:10.2337/diabetes.53.7.1643 · Cited by 455
Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance
Matthews, V. B., Allen, T. L., Risis, S., Chan, M. H. S., Henstridge, D. C., Watson, N., Zaffino, L. A., Babb, J. R., Boon, J., Meikle, P. J., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1865-y · Cited by 334 · cited 1×
“In the present context, it is important to note that IL-6deficient mice develop mature-onset obesity, hepatic inflammation and systemic insulin resistance (Wallenius et al., 2002; Matthews et al., 2010).”
BackgroundInterleukin-6 regulates pancreatic α-cell mass expansion
Ellingsgaard, H., Ehses, J. A., Hammar, E. B., Van Lommel, L., Quintens, R., Martens, G., Kerr-Conte, J., Pattou, F., Berney, T., Pipeleers, D., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801059105 · Cited by 269
Differences in Wound Healing in Mice with Deficiency of IL-6 versus IL-6 Receptor
McFarland-Mancini, M. M., Funk, H. M., Paluch, A. M., Zhou, M., Giridhar, P. V., Mercer, C. A., Kozma, S. C., & Drew, A. F. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901929 · Cited by 249 · cited 1×
“In addition to JAK/ STAT activation, the SRC homology domain 2-containing tyrosine phosphatase 2 (SHP-2) is recruited to its binding site on gp130 and phosphorylated to initiate the MAPK cascade (Heinrich et al., 2003; McFarland-Mancini et al., 2010).”
BackgroundGarbers, C., Jänner, N., Chalaris, A., Moss, M. L., Floss, D. M., Meyer, D., Koch-Nolte, F., Rose-John, S., & Scheller, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.229393 · Cited by 201
Cited by
Zhang, C., Wu, Z., Li, J.-W., Zhao, H., & Wang, G.-Q. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105954 · Cited by 1,758
Catanzaro, M., Fagiani, F., Racchi, M., Corsini, E., Govoni, S., & Lanni, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0191-1 · Cited by 605
Flavonoids as Cytokine Modulators: A Possible Therapy for Inflammation-Related Diseases
Leyva-López, N., Gutierrez-Grijalva, E., Ambriz-Perez, D., & Heredia, J. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060921 · Cited by 337
“Nevertheless, LU8C-FP failed to inhibit IL-1β and IL-8 expression, which provide information leading to the use of this flavonoid to treat inflammatory diseases caused by IL-6 [98], such as colitis, diabetes, rheumatoid arthritis, cancer and cardiovascular diseases [99–103].”
BackgroundNilsson, M. B., Sun, H., Diao, L., Tong, P., Liu, D., Li, L., Fan, Y., Poteete, A., Lim, S.-O., Howells, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aao4307 · Cited by 146
(2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.07.012 · Cited by 46
Metadata
- Authors
- Qu, D., Liu, J., Lau, C. W., & Huang, Y.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2014-07-17
- Volume
- 171
- Issue
- 15
- Pages
- 3595-3603
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2149053203
- Cited by
- 159
- References
- 23
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.